This round is no longer accepting investments, but others just like it are live now.

CLOSED

GET A PIECE OF IHEALTHSCREEN

AI-Driven Disease Screening Software

iHealthScreen is an AI-driven HIPAA-compliant med-tech company with incoming product traction in several international markets, using AI to Scalably Screen for Retinal Diseases, Stroke, and Heart Disease. Early diagnosis and intervention can prevent blindness, save countless lives & eliminate massive amounts of downstream spending. iHealthScreen is in the pre-revenue stage of development. Some of the information on the campaign page was obtained via the Company's relationship with iHealthScreen Ltd. (Abu Dhabi), which is an LLC, also owned by Alauddin Bhuiyan, PhD, CEO. There is a software license agreement between the two entities, allowing iHealthScreen Ltd. to use the Company's IP and software portfolios.

Show more

This Reg CF offering is made available through StartEngine Capital, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.
Company Image

$184,788.66 Raised

REASONS TO INVEST

Reasons Icon

iHealthScreen is entering what we believe is almost an entirely untapped, multi-billion-dollar global market ($9.5B in USA only). With regulatory approvals already achieved in key markets, along with the established reimbursement code for screening in place approved for European and most of the Asian markets, we believe iHealthScreen is poised to successfully commercialize its products. iHealthScreen’s first product, iPredictTM, is market ready, with one patent received and multiple patents pending, and we’re anticipating AMD & DR FDA 510(K) clearances by mid-2023. Already having a large hospital chain as a customer and a licensing agreement is in place with one of the top camera companies in the world, we believe demonstrates traction with key strategic partners.

Reasons Icon

To the best of our knowledge, iHealthScreen is the first company in the world to receive CE certification for three blinding eye disease screening: AMD, DR, and glaucoma. In addition, iHealthScreen has developed and validated prediction models for strokes, heart attacks, and cardiovascular diseases. We have seen stroke and heart attack prediction accuracy is almost 10% higher than the existing clinically used prediction models (Framingham and CHADS scores), with additional tools in development phase for Alzheimer’s and dementia prediction.

Reasons Icon

iHealthScreen has been awarded $2.7M in NIH funding, raised $750K as seed funding and we are working on securing additional research grants. We have received one US patent (the first patent in Late AMD prediction), one patent is pending and four provisional patent applications are submitted. The company’s work on retinal disease screening is featured in the world's largest ophthalmology conference ARVO 2018, and the American Academy of Ophthalmology (AAO) 2020. The stroke prediction results were presented at the Society for Brain Mapping Conference 2021.

TEAM

Alauddin Bhuiyan, PhD

Alauddin Bhuiyan, PhD • Founder and CEO

Dr. Alauddin Bhuiyan is an inventor, innovator, and computer scientist with deep life science and medical technology expertise covering the spectrum of life science and med-tech. He is the founder and CEO of iHealthScreen Inc. and has been working in the retinal imaging and image-based disease screening area for more than 15 years. He has been with the company as full-time since January 2017. Before that, he was a faculty member in the department of Computer Science at New York University. He was a visiting scholar at Harvard Medical School and was the recipient of the prestigious Endeavor Australia Award 2014 and was recognized as a distinguished Australian. He has been holding an Adjunct Associate Professor position at New York Eye and Ear Infirmary, Icahn School of Medicine at Mount Sinai since July 01, 2019.

Dr. Bhuiyan led the developing iPredictTM a HIPAA-compliant AI-powered software tool, which is based on Electronic Health Record (EHR) and telemedicine platform to screen and predict individuals at risk of diabetic retinopathy (DR), Age-related Macular Degeneration (AMD), Glaucoma, heart disease and stroke (https://iPredict.health).

The AMD, DR, and glaucoma screening tools are already CE certified, Abu Dhabi Health and Australian Health approved.

Dr. Bhuiyan is the inventor of the first image-based prediction tool for age-related macular degeneration (AMD). A full US patent is awarded to iHealthScreen Inc. This work was selected as featured work at ARVO 2018, the largest ophthalmology conference in the world. Also, the American Academy of Ophthalmology selected his work for the panel discussion in 2020. His interview can be viewed at https://macularnews.org/2018/06/07/arvo-2018-alauddin-bhuiyan-phd/

Dr. Bhuiyan has received almost $5M Federal and state grants through various stages of his career. He secured more than $2.7M grants (another $2.2M is under consideration) for his company through NIH SBIR grants a Principal Investigator. 

Dr. Bhuiyan received his Ph.D. from the University of Melbourne, Australia, one of the top universities in the world (No. 1 in Australia). He joined at the Centre for Eye Research Australia (CERA) as a post-doctoral research fellow in 2009. Following this - in 2011, he joined at Commonwealth Scientific and Industrial Research Organization (CSIRO, which is the inventor of WiFi Technology) as a research scientist.

While at CSIRO, Dr. Bhuiyan developed a software tool that can predict an individual’s genetic association with Alzheimer’s disease, a patented technology currently being used by Neurovision.

As an innovator and technology developer, he has been at the core of medical products and technologies which have transformed the ophthalmic field and are impacting medical care for hundreds of thousands of patients every year.

Dr. Bhuiyan is a holder of multiple issued and pending patents. He has multiple high-impact publications in the field and published more than a hundred research articles, which have been cited by more than a thousand peer-reviewed publications. He is a senior member of IEEE Computer Society and IEEE Engineering in Medicine and Biology. He served on the technical committee for many IEEE conferences and journals.

Read More

Travis Millman, MAPP

Travis Millman, MAPP • Strategic Advisor

As a startup veteran with a penchant for developing and launching breakthrough products, Travis has played many roles during the course of his career. He was as Chief Operating Officer at Neuvotion, an early-stage medical device startup working on a next generation approach to neuromuscular electrical stimulation. He has been working on everything from the headiest of strategy development and refinement to the block and tackling aspects of building and growing a company.

Travis works 1 hour per week on iHealthscreen

Read More

Ms. Kathleen Adams, MBA

Ms. Kathleen Adams, MBA • Chief Marketing Officer

The clinical innovations patients need require integrating the benefits of several domains: biotech, pharma, diagnostics, genomics, and digital health. Having worked in all of these areas gives me the breadth and range to excel at cross-functional leadership, and the passion to keep the patient in mind. 

From market assessment to launch and implementation, I focus on new approaches to healthcare, particularly for life-threatening illnesses. Discoveries and inventions are essential, but not sufficient, to improving healthcare: closing the gap between new capabilities and the realities of care delivery is the only route to meaningful change for the better.

I nurture innovations -- new disease insights, new therapeutic or diagnostic technologies -- by working backward from the patient or provider, while others on the team work forward from the science. I've worked in marketing, business development, technology evaluation and patient advocacy roles at diagnostics companies, clinical laboratories and pharma and biotechnology companies, conducting pre-market evaluations, producing and executing development plans, and leading product launch campaigns for pharmaceutical and diagnostic products, as well as a suite of targeted diagnostic services. I've led commercial teams and strategic initiatives, served on a corporate board and a senior management team, and influenced at the senior executive level to bring about institutional change and enable new approaches to team-driven development.

My experience in establishing coalitions across the for-profit/not-for-profit divide, as well as my interdisciplinary team leadership efforts, are growing in relevance during this period of rapid industry restructuring and technology advancements. The explosion of health information and new technologies occurring simultaneously with the shift of decision-making responsibility to patients/consumers is driving change in a challenging way. The potential for more relevant, focused and personalized care is evident; the potential risks to patients without a deep understanding of science and medicine are daunting. Attention to health literacy, patient-centered research and implementation science are essential to help us optimize the benefits of new approaches. 

Ms. Kathleen Adams works 8-16 hours per week on iHealthscreen

Read More





the pitch

iHealthScreen is bringing low-cost, AI-driven screening software to primary care offices around the world to provide routine access to disease prevention that would otherwise be limited to specialty care. We’ve been awarded $2.7M in NIH funding and are in the process of receiving an additional $6.5M from private investors and research grants, with one patent received and multiple patents pending. Our first product, iPredictTM, has the capability to screen for late age-related macular degeneration (AMD), diabetic retinopathy (DR), glaucoma, stroke, heart attack, and cardiovascular heart disease, and we have additional tools in development for Alzheimer’s, dementia and hypertensive retinopathy. By facilitating large-scale, low-cost screening, our software presents wide-reaching impact and huge potential for growth.




A New Leader in AI-Driven Disease Prevention


iHealthScreen’s integrated, retinal imaging-based system makes us one of the first companies in the world to receive CE certification, Australian and UAE Health approvals for AMD, DR, and glaucoma screening. We’re already gaining international traction with contracts in the US, EU, Bangladesh, and UAE, and have been collaborating with Global Victoria, Australia. 



iHealthScreen is poised to be a leader in this new area of AI-driven disease prevention, providing critical value to individuals, medical providers, and insurance providers and presenting enormous growth potential to investors.




The Problem & Our Solution


Preventative Screening Should Be Easy, Fast, and Accessible

Our current medical systems—the US serving as the most glaring example—cost patients and providers billions of dollars while often failing to improve overall health outcomes, especially at a preventive level. Primary care doctors lack the resources to provide more than the most basic screenings, and most people don’t have the time or resources to schedule regular screenings with specialists. This results in serious health consequences and large financial burdens, for patients, providers, and insurers alike.



*The features shown in the graphic above reflect features for a product that has not received FDA 510K clearance. The product is not currently available to the general public for sale.


iHealthScreen’s software makes preventative screening for ailments such as eye disease, diabetes, cardiovascular disease, heart attack and stroke easy, fast, and accessible. By lowering costs and expanding access, we’re looking to make screening for a larger set of diseases a seamless, built-in component of your annual check-up, especially for aging patients. In addition to our screening software, we’re aiming to add a built-in telemedicine capability to ensure patients can receive immediate care when and wherever needed. 



The Market & Our Traction


A Newly Opened, Multi-Billion-Dollar Global Market

The current market size for screening diabetic retinopathy (DR) and age-related macular degeneration (AMD) is projected at $9.5B, in USA only, with the global diabetic population estimated to reach 578 million by 2030, it should be 3x. 


(source)


The introduction of CPT code 92229 in 2021 has opened up the screening market, allowing coverage for retinal imaging for the detection or monitoring of disease. As of now, this massive market is almost entirely untapped, we believe less than 1% of the market is taken by companies that have received FDA 510(K) clearance—providing ideal timing for iHealthScreen’s FDA clearance and market entry. FDA 510K application on AMD screening is already submitted. The 510K application for DR screening is in the final stage of submission. The company expects to obtain these two FDA 510K clearances by the middle of this year and achieve an advantageous position to become commercially successful.


iHealthScreen’s first product, iPredictTM, is market ready, with one patent received and multiple patents pending, and we’re anticipating FDA 510(K) clearance by mid-2023. We’re now one of the first companies in the world to receive CE certification for AMD, DR, and glaucoma screening, and have received approval from Health Australia and Health UAE.



We’ve secured a total of $2.7M in NIH funding, which is being applied towards a three-year prospective trial on late AMD prediction, along with a NIH SBIR Phase II grant for stroke prediction. We’ve signed a licensing agreement with iCare in Finland, an agreement with the Bangladesh Diabetes Society to screen 5.5 million registered diabetics in Bangladesh, as well as another with Burjeel Hospital UAE for DR screenings which has 40 clinics in the Gulf region with billions of dollars in revenue (source).



Why Invest


Invest in the Future of Preventive Healthcare

Streamlined, hassle-free disease screening should be a part of every patient’s annual routine. We’re looking at huge potential for growth, scale, and global impact—and we believe now is the perfect time to join us. 


Invest in iHealthScreen & help us on our mission to provide low-cost, advanced screening software in primary care offices across the world - help prevent blindness, deaths and disability. 



*The features shown in the graphic above reflect features for a product that has not received FDA 510K clearance. The product is not currently available to the general public for sale.

ABOUT

HEADQUARTERS
132-02 89th Av, Suite 214
Richmond Hill, NY 11418
WEBSITE
View Site
iHealthScreen is an AI-driven HIPAA-compliant med-tech company with incoming product traction in several international markets, using AI to Scalably Screen for Retinal Diseases, Stroke, and Heart Disease. Early diagnosis and intervention can prevent blindness, save countless lives & eliminate massive amounts of downstream spending. iHealthScreen is in the pre-revenue stage of development. Some of the information on the campaign page was obtained via the Company's relationship with iHealthScreen Ltd. (Abu Dhabi), which is an LLC, also owned by Alauddin Bhuiyan, PhD, CEO. There is a software license agreement between the two entities, allowing iHealthScreen Ltd. to use the Company's IP and software portfolios.

TERMS

iHealthScreen
Overview
PRICE PER SHARE
$2.63
DEADLINE
Aug. 2, 2023 at 6:59 AM UTC
VALUATION
$24.98M
FUNDING GOAL
$10K - $1.23M
Breakdown
MIN INVESTMENT
$189.36
MAX INVESTMENT
$1,234,998.03
MIN NUMBER OF SHARES OFFERED
3,802
MAX NUMBER OF SHARES OFFERED
469,581
OFFERING TYPE
Equity
SHARES OFFERED
Common Stock

Maximum Number of Shares Offered subject to adjustment for bonus shares

*Maximum number of shares offered subject to adjustment for bonus shares. See Bonus info below.

Voting Rights of Securities Sold in this Offering

Voting Proxy. Each Subscriber shall appoint the Chief Executive Officer of the Company (the “CEO”), or his or her successor, as the Subscriber’s true and lawful proxy and attorney, with the power to act alone and with full power of substitution, to, consistent with this instrument and on behalf of the Subscriber, (i) vote all Securities, (ii) give and receive notices and communications, (iii) execute any instrument or document that the CEO determines is necessary or appropriate in the exercise of its authority under this instrument, and (iv) take all actions necessary or appropriate in the judgment of the CEO for the accomplishment of the foregoing. The proxy and power granted by the Subscriber pursuant to this Section are coupled with an interest. Such proxy and power will be irrevocable. The proxy and power, so long as the Subscriber is an individual, will survive the death, incompetency and disability of the Subscriber and, so long as the Subscriber is an entity, will survive the merger or reorganization of the Subscriber or any other entity holding the Securities. However, the Proxy will terminate upon the closing of a firm-commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933 covering the offer and sale of Common Stock or the effectiveness of a registration statement under the Securities Exchange Act of 1934 covering the Common Stock.

Investment Incentives & Bonuses*

Time-Based:

Friends and Family Early Birds

Invest within the first 48 hours and receive 15% bonus shares.

Super Early Bird Bonus

Invest within the first week and receive 10% bonus shares.

Early Bird Bonus

Invest within the first two weeks and receive 5% bonus shares.

Amount-Based:

$1,000+ | Tier 1

Invest $1,000 and receive access 2% Bonus Shares.

$2,500+ | Tier 2

Invest $2,500 and receive access 3% Bonus Shares.

$5,000+ | Tier 3

Invest $5,000 and receive access 5% Bonus Shares.

$10,000+ | Tier 4

Invest $10,000 and receive access 10% Bonus Shares + zoom call with iHealthScreen’s founder.

*In order to receive perks from an investment, one must submit a single investment in the same offering that meets the minimum perk requirement. Bonus shares from perks will not be granted if an investor submits multiple investments that, when combined, meet the perk requirement. All perks occur when the offering is completed.

The 10% StartEngine Owners' Bonus

iHealthScreen, Inc. will offer 10% additional bonus shares for all investments that are committed by investors that are eligible for the StartEngine Crowdfunding Inc. OWNer's bonus.

This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example, if you buy 100 shares of Common Stock at $2.63 / share, you will receive 110 shares of Common Stock, meaning you'll own 110 shares for $263. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.

This 10% Bonus is only valid during the investors eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are canceled or fail.

Investors will receive the highest single bonus they are eligible for among the bonuses based on the amount invested and time of offering elapsed (if any). Eligible investors will also receive the Owner’s Bonus in addition to the aforementioned bonus.

Irregular Use of Proceeds

The Company will not incur any irregular use of proceeds.

PRESS

Article Image
Bloomberg

iHealthScreen’s Artificial Intelligence (AI) Based Tool Can Accurately Diagnose Age-Related Macular Degeneration (AMD) and

Article Image
Yahoo Finance

HealthScreen Completed Prospective Trial of AI-Based Tool for Age-Related Macular Degeneration (AMD) Screening and Submitting the Results to FDA for 510K Clearance

Article Image
Diagnostic and Interventional Cardiology

iHealthScreen Inc. Introduces An Automated Stroke Prediction Model, based on AI and Color Fundus Imaging

Article Image
Business Wire

iHealthScreen Inc. is Awarded US Patent on Late Age-related Macular Degeneration (AMD) Prediction Model, which is based on AI and Color Fundus Imaging

ALL UPDATES

08.02.23

A note from the CEO of iHealthScreen on closing the StartEngine Campaign

Dear Investors and Followers,

Today, we are closing the StartEngine campaign. I would like to thank you once again for your investment and for supporting the campaign. 

The bridge funding through this StartEngine campaign has already reached $225,249.22, I would like to mention here that we have received  2 written LOIs from an Angel and a VC firm - a total of $2 Million. Following the StartEngine campaign, we will keep working to complete this pre-series A round of $5M.   

I hope you will join our investors' team if you have not done so after looking into these points. Before closing, I would like to add here the highlights.


 iHealthScreen's accomplishments till mid-2023 (Highlights):                

                  We believe we are the world's first company, submitted 2 FDA 510K clearances: Diabetic Retinopathy (DR) screening and Age-related Macular Degeneration Screening using AI.             

                 We believe we are the world's first company, received CE Certification, Australian Health approval, and Abu Dhabi Health approval for Early Diagnosis of Diabetic Retinopathy (DR), Age-Related Macular Degeneration (AMD), and Glaucoma.               

                  Using iPredict - more than 10,000 people have already been screened.              

                  Awarded $2.7M of NIH SBIR grants on Stroke and Late AMD screening and prediction.             

                  Received one US Patent  the first patent in this area) for Predicting Late Age-related Macular Degeneration.                                   Filed 1 US Patent application on glaucoma detection (expedited application) 

                  3 non-provisional patent applications for 4 disease predictions:  i) stroke and heart attack prediction, ii) glaucoma detection, and iii) brain white matter lesion for Alzheimer's/Dementia prediction.             

                 Received insurance reimbursement approval in Abu Dhabi (United Arab Emirates).             Signed a licensing agreement with iCare Inc., a top color fundus camera company.  

               Stroke and heart attack prediction models are validated against an external dataset and are now ready for clinical trials 

                 Waiting for an NIH SBIR Phase II grant outcome of $2.2M).              

                  An NDA was signed with large drug company to start collaboration on the Late AMD prediction model·                                            First prediction model for Late AMD (first US patent); featured work at ARVO 2018 (interviewed by Macular News); Featured at American Academy of Ophthalmology (AAO) 2020.               

                  AMD, DR, and Glaucoma results are published in the top journals and presented/featured at the ARVO, and Selected for Panel discussion at the American Academy of Ophthalmology (AAO) conference.                 

                  Selected in the START-UP New York Program (10 years tax-free (sales, procurement, and payroll taxes) in NY state and NY City).                

                   Accepted by the  HUB71 program in Abu Dhabi, a govt. funded prestigious acceleration program in the  Middle East with AED 500K support (equivalent to USD 139K).                  

                    Company has customers, which are top hospitals and clinics in UAE and Australia - up to $B revenue.                            

                   Featured by NIH Media, Bloomberg, Yahoo Finance, Retina Today, and many other prestigious news channels.


I look forward to bring you more excited updates by team iHealthScreen.


Sincerely yours,


Alauddin


-------

Alauddin Bhuiyan, Ph.D.

Founder and CEO, iHealthScreen

08.01.23

Final Day to Invest in iHealthScreen!


Hello, iHealthScreen Community! 


It’s time to graduate from potential investor to shareholder!


Our mission is to provide low-cost, advanced screening software in primary care offices worldwide. Our technology pinpoints critical health issues in advance, helping to prevent blindness, disability, and death. 


Ready to take the leap? The time is now to get in on the multi-billion-dollar market opportunity! Our time on StartEngine is limited. 


Stand-Out Highlights


  • $2.7M in NIH funding and raised $750K as seed funding.

  • One patent was received, and multiple patents are pending.

  • Entering the $16.75B US market for disease prevention and early detection.


Make a difference right from your phone and invest today! To invest in iHealthScreen, simply visit our StartEngine campaign page. It only takes a few easy steps to become a valued investor! 


Warmly,

Alauddin Bhuiyan

08.01.23

Submitted the FDA 510K application for Diabetic Retinopathy (DR) Screening

Dear Investors and Followers,

I am happy to inform you that iHealthScreen has submitted the FDA 510K application for Diabetic Retinopathy (DR) screening. 

Why this is significance? We are the first company in the world which completed two prospective trials in USA (in collaboration with Mount Sinai School of Medicine, New York) and submitted two FDA 510K applications: 

                1) Age-related Macular Degeneration Screening (AMD) and 

                2) Diabetic Retinopathy Screening (DR)

Earlier we met with FDA in the pre-submission meeting and we are confident that these tools will be cleared by FDA by the end of this year.

We note that these tools along with glaucoma detection/screening are CE certified and ready to be used in EU, Australia (Australian Health (TGA) Approved), UAE (UAEHealth Approved). With CE we are also ready to register in UK and Ireland. Currently, a number of top hospitals/clinics are using iPredict in UAE and we are also starting operations in Melbourne Australia at one of the top Endocrinology clinics (Endocrinology Melbourne which has 18 Diabetologists).

What does this mean? With the regulatory approvals, we have mitigated the risks. With customers from the top hospital settings, we are in the process of revenue generation and scaling.

Join us in this great journey and lead the screening market which is an emerging healthcare area.

Thank you.


-------

Alauddin Bhuiyan, Ph.D.

Founder and CEO, iHealthScreen 

 


 

07.28.23

The Campaign Countdown Continues!


Hello, iHealthScreen Community! 


The clock is ticking! Our investment window is closing faster than you think. We're on a mission to provide low-cost, advanced screening software in primary care offices worldwide. Our technology pinpoints critical health issues in advance, helping to prevent blindness, disability, and death. 


We’re Taking Advantage of a Massive $9.5B Market Opportunity.


Potential investors, we encourage you to act swiftly. To invest in iHealthScreen, simply visit our StartEngine campaign page. It only takes a few easy steps to become a valued investor! This is your chance to contribute to making a tangible difference in the world! 


Warmly,

Alauddin Bhuiyan

07.25.23

iHealthScreen Q&A Webinar Recap!


Hello, iHealthScreen Community! 


Watch our webinar recap to learn about our unique opportunity to capitalize on AI-driven health screening software. CEO Alauddin Bhuiyan, CMO Thomas Gerson, and CMO Kate Adams hosted the online event!


We discussed how we're the world's first CE-certified screening tool for AMD, DR, and glaucoma screening. 


You can watch the full webinar recap here. 


Investment Highlights:


  • Raised $750K as seed funding.

  • Awarded $2.7M in NIH funding.

  • Working on securing additional research grants.

  • One US patent (the first patent in Late AMD prediction).

  • One patent is pending, with four provisional patent applications submitted.

  • FDA 510K submission is completed for AMD; DR (in a few weeks).

  • iHealthScreen significantly reduces the risk of investment as it's product iPredict is already approved in EU, Australia and most Asian countries


Be sure to spread the word and let your friends, family, and network! Ready to take the leap? Take action and join our investor community on StartEngine with tons of exciting perks!


Warmly,

Alauddin Bhuiyan



07.19.23

iHealthScreen is moving from pre-revenue to revenue stage

Dear Investors and followers,

I am pleased to inform you that Burjeel hospital UAE (a large multi-Billion $ hospital chain in Middle East ) which is our first customer in UAE has received the insurance reimbursement offer for iPredict screening AED 170 (approx. $48). The hospital is now negotiating for AED 200 and soon, will sign the reimbursement amount with the major govt insurance. This means that iHealthScreen will be in the revenue potentially from August 01. The hospital leadership indicated rolling out to all Burjeel locations (40 locations in the Middle East). The company is already in a verbal agreement to sign the DR screening with Mediclinic Middle East, another top hospital chain in UAE, and sent the contract to sign. The two hospital chains are a potential multimillion-dollar screening revenue for iHealthScreen in the future. The company has already signed contracts with 3 other clinics and is in the process of signing with a large govt. hospital chain. 


I am also pleased to inform you that iHealthScreen Australia signed the contract for diabetic retinopathy screening with Endocrinology Melbourne, Australia, which is a large Diabetes treatment clinic in Melbourne (18 clinicians) with a huge number of diabetic patients. The company will receive $10 per patient screening. The company is in a close collaboration with ACADI - Australian Centre for Accelerating Diabetes Innovations, and aims to expand to the other major hospital chains in Australia.


I am happy to mention here that our documentation on FDA 510K submission for diabetic retinopathy (DR) screening is already in the final stage and will be submitted by this Monday, the 24th. We have submitted the FDA 510K application for age-related macular degeneration (AMD) screening. These two submissions will make iHealthScreen the first company to submit two indications. 


I hope to keep you posted about the updates.


Best regards,


Alauddin


----

Alauddin Bhuiyan, Ph.D.

Founder and  CEO, iHealthScreen   


 

07.18.23

Updates from the CEO on current fundraising status

Dear investors and StartEngine followers,

Thank you for your investment and following our StartEngine campaign. I am happy to update you that we have reached 100 investors and 400+ followers. 

In this pre-Series A round, we are raising $5M, out of which approximately $1M is targeted from StartEngine. We already received 2 LOIs of $2M from 1 angel and one VC. We are closely working with several others to complete this $5M round. We aim to close this round by this December.

The StartEngine campaign is having an end date of just 2 weeks plus. Therefore, I urge you, if you are interested, please invest. We may extend the campaign date  make the target $1M if StartEngine policy allows and also, if we see a good number of investment is coming in these two weeks.     

I would like to give you confidence that you are part of a company (or planning to become a part of the company) that is top in this area. The evidence is can be shown by the recent NIH media coverage and featured by the NIH media which is highly prestigious. 

https://www.nei.nih.gov/about/news-and-events/news/ai-based-systems-can-help-identify-rapidly-advancing-age-related-macular-degeneration

We were the first to predict Late AMD and also received the first patent. Our work was discussed in the panel of the American Academy of Ophthalmology (AAO) 2020 and ARVO (the world's largest Ophthalmology conference), 2018 where I was interviewed by the macular news.

We have customers (Burjeel Hospital in UAE, a $B company) and we are in the process of generating revenue which will be start in a few weeks. We submitted one FDA and the other one is in the process of submission shortly - with the completion of the clinical trials with Mount Sinai, NY (both AMD and DR). This will make us the first company which submitted two FDA - please note that we had two FDA presubmission meetings and we are well prepared with the application.    

I thank you once again. Those who invested already - congratulations! You are part of a great company, the future of the healthcare/med-device. Those who are considering - please do invest ASAP as we are chasing the closing date!

YOUR INVESTMENT IS ALREADY IN THE LOW RISK CATEGORIES - We are CE Certified, and Australian Health and UAE Health approved. We are also applying for UK and Canada health approvals - with CE certification, it is straight forward). WITH 2 FDA CLEARNACES, WE ARE PROJECTING 10x HIGHER VALUATION IN THE NEXT 10 YEARS.

We are now discussing with a number of hospital chains in UAE and Australia for licensing our screening tools. We also signed an NDA with Alexion which is a $B drug company on our Late AMD prediction tool - for licensing. I will keep you posted.

I hope to bring you more news -

Best regards,


-----

Alauddin Bhuiyan, Ph.D.

Founder and CEO, iHealthScreen



   


07.18.23

Screening Prevents Blindness and Saves Lives!

Hello, IHealthScreen Community! 


Life-Saving, Med Tech Investment Opportunity! 


Did you know that 2 of the top 5 causes of death are not detected? This doesn't include the additional 40%+ of at-risk populations that are not being screened at all.


It's time to be proactive with our health. Our low-cost, AI-driven screening software brings predictive technology to primary care offices worldwide!


What you need to know: 


  • Every diabetic patient is at risk of Glaucoma. 

  • 50% of diabetic patients worldwide are undiagnosed.

  • Individuals above 50 are at risk of Age-related macular degeneration.

  • All diabetic patients are at risk of Glaucoma.

  • 35M diabetic people in the USA and 463M people worldwide are at risk of Duane-Radial Ray Syndrome (DR). (85% of diabetic people are at risk of DR).


Accessible, affordable screening for DR, AMD, and Glaucoma is vital for patients to receive sight-saving treatment. 


We can provide accessible health screenings for:


  • Blinding diseases- glaucoma, diabetic retinopathy, macular degeneration. 

  • Systemic diseases- Stroke, heart attacks, cardiovascular diseases (eg, Atherosclerosis, Atrial fibrillation, + more).  

  • Additional tools in development for Alzheimer’s and dementia.


Join us in disrupting this multi-billion-dollar market opportunity on StartEngine! 


Warmly,

Alauddin Bhuiyan



07.10.23

Full US Patent Application on Glaucoma Detection was Submitted

Dear shareholders and potential investors/followers,

We are very happy to inform you that we have submitted a non-provisional US patent (full patent) application# 18/219,433 has been submitted today: 07/08/2023. This is an expedited application and is expected to receive the review within 6 months. Please take a look at the attached snapshot of the submission info. As the CEO of the company, I personally thank the technical team and our patent attorney Mr. George Likourezos.   

If this patent is awarded, this will be a highly significant addition to our track record. Please note that we received a full US patent on Late Macular Degeneration Screening and Prediction, last year (certificate attached). iPredict also received US trademark (certificate attached). We have filed a non-provisional patent application on stroke, heart attack prediction, and retinal layer segmentation from OCT imaging.

For completeness, I have attached a photograph (images of the diseases on our current focus areas of screening and prediction) which shows the glaucoma patient's vision.

You may know that half of the glaucoma patients in the world are undiagnosed, and a leading cause of blindness. 

Someone should be screened for glaucoma if the following risk factors apply: 

      - Every diabetic patient is at risk of glaucoma. 

      - Family of history of glaucoma

      - Black ethnicity

      - Above 60 years

      - Physical Injury to the eye  

      - A few eye-related risk factors (e.g., eye anatomy, namely thinner corneas and optic nerve sensitivity)

Medicare covers glaucoma screening from the age of 65 (depending on the insurance). National Eye Institute recommends glaucoma screening when someone reaches the age of 40, and annually or bi-annually from 50.

iPredict-glaucoma screening achieved above 94% accuracy on a publicly available dataset. We aim to apply for FDA approval in the future following the completion of the prospective clinical trials. So, far we have completed two prospective trials on AMD and DR screening, and our FDA 510K application on AMD is submitted to FDA, and DR will be submitted in a week or two (documents are in the final preparation).  

I hope to update you with more exciting news in the near future.

Best regards,

Alauddin

---

Alauddin Bhuiyan, Ph.D.

Founder and CEO, iHealthScreen

  


 

  


07.07.23

🚨Limited Time to Register! 🚨

📣Time is running out to join our webinar on July 11th at 9:00 AM PST! 📣

🔔Don’t forget that CEO Alauddin Bhuiyan is hosting an iHealthScreen exclusive webinar! Find out what makes our crowdfunding raise on StartEngine an attractive investment. 

Additional speakers:

  • CMO Thomas Gerson has successfully led $100M+ for 3 companies previously through his CFO position. 

  • CMO Kate Adams was the former Director at Quest, a multi-billion dollar company.

This is your chance to capitalize on AI-driven health screening software (as a service, SaaS). Our integrated, retinal imaging-based system makes us one of the first companies in the world to receive CE certification and Australian and UAE Health approvals for AMD, DR, and glaucoma screening. FDA 510K submission is completed for AMD; DR (in a few weeks). 

🚨5 days left to register! Sign up here. 🚨

Be sure to spread the word and let your friends, family, and network in on this online event! Ready to take the leap? Take action and join our investor community with tons of exciting perks!

Warmly,
Alauddin Bhuiyan
Founder and CEO
iHealthScreen


REWARDS

Multiple investments in an offering cannot be combined to qualify for a larger campaign reward.

10%

Stack Venture Club & Rewards!

Members get an extra 10% shares in addition to rewards below!

Venture Club

Venture Club

Venture Club Members earn 10% bonus shares on top of this and all eligible investments for an entire year. Not a member? Sign up at checkout ($275/year).

$1,000

Tier 1

Invest $1,000 and receive access 2% Bonus Shares.

$2,500

Tier 2

Invest $2,500 and receive access 3% Bonus Shares.

$5,000

Tier 3

Invest $5,000 and receive access 5% Bonus Shares.

$10,000

Tier 4

Invest $10,000 and receive access 10% Bonus Shares + zoom call with iHealthScreen’s founder.

JOIN THE DISCUSSION

0/2500

KS
Karl Stine

2 years ago

How does this system compare to other products currently available such as Eyenuk that can bill under CPT 92229?

Show more

2

0

AB
Alauddin Bhuiyan

iHealthScreen

2 years ago

This is the same screening as DIABETIC RETINOPATHY. In addition, we have submitted FDA 510K of age-related macular degeneration screening, as the first company.

Show more

0

HOW INVESTING WORKS

Cancel anytime before 48 hours before a rolling close or the offering end date.

FAQ Timeline

WHY STARTENGINE?

Rewards Icon
REWARDS

We want you to succeed and get the most out of your money by offering rewards and memberships!

Lock Icon
SECURE

Your info is your info. We take pride in keeping it that way!

Ellipse Icon
DIVERSE INVESTMENTS

Invest in over 200 start-ups and collectibles!

FAQS

With Regulation A+, a non-accredited investor can only invest a maximum of 10% of their annual income or 10% of their net worth per year, whichever is greater. There are no restrictions for accredited investors.

With Regulation Crowdfunding, non-accredited investors with an annual income or net worth less than $124,000 are limited to invest a maximum of 5% of the greater of those two amounts. For those with an annual income and net worth greater than $124,000, they are limited to investing 10% of the greater of the two amounts.

At the close of an offering, all investors whose funds have “cleared” by this time will be included in the disbursement. At this time, each investor will receive an email from StartEngine with their Countersigned Subscription Agreement, which will serve as their proof of purchase moving forward.

Please keep in mind that a company can conduct a series of “closes” or withdrawals of funds throughout the duration of the campaign. If you are included in that withdrawal period, you will be emailed your countersigned subscription agreement and proof of purchase immediately following that withdrawal.

StartEngine assists companies in raising capital, and once the offering is closed, we are no longer involved with whether the company chooses to list shares on a secondary market or what occurs thereafter. Therefore, StartEngine has no control or insight into your investment after the close of the live offering. In addition, we are not permitted to provide financial advice. You may want to contact a financial professional to discuss possible investment outcomes.

For Regulation Crowdfunding, investors are able to cancel their investment at any point throughout the campaign up until 48 hours before the closing of the offering. Note: If the company does a rolling close, they will post an update to their current investors, giving them the opportunity to cancel during this timeframe. If you do not cancel within this 5-day timeframe, your funds will be invested in the company, and you will no longer be able to cancel the investment. If your funds show as ‘Invested’ on your account dashboard, your investment can no longer be canceled.

For Regulation A+, StartEngine allows for a four-hour cancellation period. Once the four-hour window has passed, it is up to each company to set their own cancellation policy. You may find the company’s cancellation policy in the company’s offering circular.

Once your investment is canceled, there is a 10-day clearing period (from the date your investment was submitted). After your funds have cleared the bank, you will receive your refund within 10 business days.

Refunds that are made through ACH payments can take up to 10 business days to clear. Unfortunately, we are at the mercy of the bank, but we will do everything we can to get you your refund as soon as possible. However, every investment needs to go through the clearing process in order to be sent back to the account associated with the investment.

Both Title III (Regulation Crowdfunding) and Title IV (Reg A+) help entrepreneurs crowdfund capital investments from unaccredited and accredited investors. The differences between these regulations are related to the investor limitations, the differing amounts of money companies are permitted to raise, and differing disclosure and filing requirements. To learn more about Regulation Crowdfunding, click here, and for Regulation A+, click here.

RAISED
$184,788.66
INVESTORS
119
MIN INVEST
$189.36
VALUATION
$24.98M

Important Message

IN MAKING AN INVESTMENT DECISION, INVESTORS MUST RELY ON THEIR OWN EXAMINATION OF THE ISSUER AND THE TERMS OF THE OFFERING, INCLUDING THE MERITS AND RISKS INVOLVED. INVESTMENTS ON STARTENGINE ARE SPECULATIVE, ILLIQUID, AND INVOLVE A HIGH DEGREE OF RISK, INCLUDING THE POSSIBLE LOSS OF YOUR ENTIRE INVESTMENT.

www.StartEngine.com is a website owned and operated by StartEngine Crowdfunding, Inc. (“StartEngine”), which is neither a registered broker-dealer, investment advisor nor funding portal.

Unless indicated otherwise with respect to a particular issuer, all securities-related activity is conducted by regulated affiliates of StartEngine: StartEngine Capital LLC, a funding portal registered here with the US Securities and Exchange Commission (SEC) and here as a member of the Financial Industry Regulatory Authority (FINRA), or StartEngine Primary LLC (“SE Primary”), a broker-dealer registered with the SEC and FINRA / SIPC. You can review the background of our broker-dealer and our investment professionals on FINRA’s BrokerCheck here. StartEngine Secondary is an alternative trading system (ATS) regulated by the SEC and operated by SE Primary. SE Primary is a member of SIPC and explanatory brochures are available upon request by contacting SIPC at (202) 371-8300.

StartEngine facilitates three types of primary offerings:

1) Regulation A offerings (JOBS Act Title IV; known as Regulation A+), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Primary, LLC (unless otherwise indicated). 2) Regulation D offerings (Rule 506(c)), which are offered only to accredited investors. These offerings are made through StartEngine Primary, LLC. 3) Regulation Crowdfunding offerings (JOBS Act Title III), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Capital, LLC. Some of these offerings are open to the general public, however there are important differences and risks.

Any securities offered on this website have not been recommended or approved by any federal or state securities commission or regulatory authority. StartEngine and its affiliates do not provide any investment advice or recommendation and do not provide any legal or tax advice concerning any securities. All securities listed on this site are being offered by, and all information included on this site is the responsibility of, the applicable issuer of such securities. StartEngine does not verify the adequacy, accuracy, or completeness of any information. Neither StartEngine nor any of its officers, directors, agents, and employees makes any warranty, express or implied, of any kind whatsoever related to the adequacy, accuracy, or completeness of any information on this site or the use of information on this site.

Investing in private company securities is not suitable for all investors. An investment in private company securities is highly speculative and involves a high degree of risk. It should only be considered a long-term investment. You must be prepared to withstand a total loss of your investment. Private company securities are also highly illiquid, and there is no guarantee that a market will develop for such securities. Each investment also carries its own specific risks, and you should complete your own independent due diligence regarding the investment. This includes obtaining additional information about the company, opinions, financial projections, and legal or other investment advice. Accordingly, investing in private company securities is appropriate only for those investors who can tolerate a high degree of risk and do not require a liquid investment. See additional general disclosures here.

By accessing this site and any pages on this site, you agree to be bound by our Terms of use and Privacy Policy, as may be amended from time to time without notice or liability.

Canadian Investors

Investment opportunities posted and accessible through the site will not be offered to Canadian resident investors. Potential investors are strongly advised to consult their legal, tax and financial advisors before investing. The securities offered on this site are not offered in jurisdictions where public solicitation for offerings is not permitted; it is solely your responsibility to comply with the laws and regulations of your country of residence.

California Investors Only – Do Not Sell My Personal Information (800-317-2200). StartEngine does not sell personal information. For all customer inquiries, please write to contact@startengine.com.

StartEngine Marketplace (“SE Marketplace”) is a website operated by StartEngine Primary, LLC (“SE Primary”), a broker-dealer that is registered with the SEC and a member of FINRA and the SIPC.

StartEngine Secondary (“SE Secondary”) is our investor trading platform. SE Secondary is an SEC-registered Alternative Trading System (“ATS”) operated by SE Primary that matches orders for buyers and sellers of securities. It allows investors to trade shares purchased through Regulation A+, Regulation Crowdfunding, or Regulation D for companies who have engaged StartEngine Secure LLC as their transfer agent. The term “Rapid,” when used in relation to transactions on SE Marketplace, specifically refers to transactions that are facilitated on SE Secondary, This is because, unlike with trades on the StartEngine Bulletin Board (“SE BB”), trades on SE Secondary are executed the moment that they are matched.

StartEngine Bulletin Board (“SE BB”) is a bulletin board platform on which users can indicate to each other their interest to buy or sell shares of private companies that previously executed Reg CF or Reg A offerings not necessarily through SE Primary. As a bulletin board platform, SE BB provides a venue for investors to access information about such private company offerings and connect with potential sellers. All investment opportunities on SE BB are based on indicated interest from sellers and will need to be confirmed. Even if parties express mutual interest to enter into a trade on SE BB, a trade will not immediately result because execution is subject to additional contingencies, including among others, effecting of the transfer of the shares from the potential seller to the potential buyer by the issuer and/or transfer agent. SE BB is distinct and separate from SE Secondary. SE Secondary facilitates the trading of securities by matching orders between buyers and sellers and facilitating executions of trades on the platform. By contrast, under SE BB, SE Primary assists with the facilitation of a potential resulting trade off platform including, by among other things, approaching the issuer and other necessary parties in relation to the potential transaction. The term “Extended”, when used in relation to transactions on SE Marketplace denotes that these transactions are conducted via SE BB, and that these transactions may involve longer processing times compared to SE Secondary for the above-stated reasons.

Even if a security is qualified to be displayed on SE Marketplace, there is no guarantee an active trading market for the securities will ever develop, or if developed, be maintained. You should assume that you may not be able to liquidate your investment for some time or be able to pledge these shares as collateral.

The availability of company information does not indicate that the company has endorsed, supports, or otherwise participates with StartEngine. It also does not constitute an endorsement, solicitation or recommendation by StartEngine. StartEngine does not (1) make any recommendations or otherwise advise on the merits or advisability of a particular investment or transaction, (2) assist in the determination of the fair value of any security or investment, or (3) provide legal, tax, or transactional advisory services.